Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7036 to 7050 of 8221 results

  1. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

  2. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    In development Reference number: GID-TA11712 Expected publication date: TBC

  3. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]

    In development Reference number: GID-TA11629 Expected publication date: TBC

  4. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

  5. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

  6. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

  7. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

  8. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

  9. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

  10. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

  11. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

  12. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

  13. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

  14. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

  15. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395